Joshua Wolf, Tom G Connell, Kim J Allison, Li Tang, Julie Richardson, Kristen Branum, Eloise Borello, Jeffrey E Rubnitz, Aditya H Gaur, Hana Hakim, Yin Su, Sara M Federico, Francoise Mechinaud, Randall T Hayden, Paul Monagle, Leon J Worth, Nigel Curtis, Patricia M Flynn
BACKGROUND: Central line-associated bloodstream infections (CLABSIs) affect about 25% of children with cancer, and treatment failure is common. Adjunctive ethanol lock therapy might prevent treatment failure but high-quality evidence is scarce. We evaluated ethanol lock therapy as treatment and secondary prophylaxis for CLABSI in children with cancer or haematological disorders. METHODS: This randomised, double-blind, placebo-controlled superiority trial, with two interim futility and efficacy analyses (done when the first 46 and 92 evaluable participants completed study requirements), was done at two paediatric hospitals in the USA and Australia...
August 2018: Lancet Infectious Diseases